David Allmond is a passionate, life sciences professional, with a particular interest in strategy development. He has an impressive multi-national leadership background and in recent years has focused his career on clinical diagnostics in infectious diseases and commercialization of medicines to tackle severely underserved, debilitating cancers and orphan diseases. His most recent post was Chief Executive Officer for Novacyt Group, an international clinical diagnostics company.
Prior to this David has held a number of senior positions across the pharmaceutical industry:
Chief Business Officer for Amryt Pharma, a global pharmaceutical company focused on developing and delivering innovative treatments to improve the lives of people with rare and orphan diseases.
President EMEA for Aegerion Pharmaceuticals where he was responsible for the EMEA P&L and was tasked with turning the business around to ensure it was fit to deliver profitable growth, after a challenging entry into the region.
General manager Celgene UK, responsible for setting up Celgene’s UK and Ireland operating company and subsequently Vice President EMEA Marketing and Market Access followed by his move to the US to assume the role of Corporate Vice President, Global Marketing for Celgene, where he played a pivotal role in defining brand and portfolio strategy.
David spent nearly 7 years on the board of Myeloma UK, a highly progressive patient group, supporting patients with Multiple Myeloma. He holds a Bachelor of Science degree in Microbiology from Imperial College, London.
